Advertisement

Recombinant Activated Factor VII: The Delicate Balance between Efficacy and Safety

  • S. Bélisle
  • J. -F. Hardy
  • P. Van der Linden
Conference paper

Abstract

Endogenous activated factor VII (FVIIa) plays a crucial role in the effective coagulation process. The clotting drug NovoSeven® (Novo Nordisk A/S, Bagsvaerd, Denmark) is structurally nearly identical to endogenous FVIIa and is produced by recombination from a baby hamster kidney cell line. Supra-physiologic concentrations of FVIIa are achieved by the administration of pharmacological doses of recombinant FVIIa (rFVIIa). To generate thrombin, rFVIIa needs either tissue factor or activated platelets (tissue factor-independent generation). Consequently, rFVIIa is approved for the prevention and the treatment of bleeding in patients with a range of congenital hemostatic disorders, mainly hemophilia. Its high efficacy in various hemostatic defects has oriented its application to the perioperative setting, trauma, and ICU patients. Over the last five years, the estimated number of patients treated with rVIIa has grown rapidly, mainly for off-license indications.

Keywords

Thromboembolic Complication Dengue Hemorrhagic Fever Spontaneous Intracerebral Hemorrhage Blood Coagul Fibrinolysis Human Coagulation Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Diprose P, Herbertson MJ, O’Shaughnessy D, Gill RS (2005) Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 95: 596–602PubMedCrossRefGoogle Scholar
  2. 2.
    Friederich PW, Henny CP, Messelink EJ, et al (2003) Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a doubleblind placebo-controlled randomised trial. Lancet 361: 201–205PubMedCrossRefGoogle Scholar
  3. 3.
    Ekert H, Brizard C, Eyers R, Cochrane A, Henning R (2006) Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 17: 389–395PubMedCrossRefGoogle Scholar
  4. 4.
    Lodge JP, Jonas S, Oussoultzoglou E, et al (2005) Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 102: 269–275PubMedCrossRefGoogle Scholar
  5. 5.
    Lodge JP, Jonas S, Jones RM, et al (2005) Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 11: 973–979PubMedCrossRefGoogle Scholar
  6. 6.
    Planinsic RM, van der Meer J, Testa G, et al (2005) Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 11: 895–900PubMedCrossRefGoogle Scholar
  7. 7.
    Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM (2005) Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth 94: 586–591PubMedCrossRefGoogle Scholar
  8. 8.
    Shao YF, Yang JM, Chau GY, et al (2006) Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg 191: 245–249PubMedCrossRefGoogle Scholar
  9. 9.
    Boffard KD, Riou B, Warren B, et al (2005) Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59: 8–15PubMedCrossRefGoogle Scholar
  10. 10.
    Bosch J, Thabut D, Bendtsen F, et al (2004) Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 127: 1123–1130PubMedCrossRefGoogle Scholar
  11. 11.
    Chuansumrit A, Wangruangsatid S, Lektrakul Y, et al (2005) Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis 16: 549–555PubMedCrossRefGoogle Scholar
  12. 12.
    Mayer SA, Brun NC, Begtrup K, et al (2005) Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352: 777–785PubMedCrossRefGoogle Scholar
  13. 13.
    Mayer SA, Brun NC, Broderick J, et al (2005) Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 36: 74–79PubMedCrossRefGoogle Scholar
  14. 14.
    Pihusch M, Bacigalupo A, Szer J, et al (2005) Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost 3: 1935–1944PubMedCrossRefGoogle Scholar
  15. 15.
    Stanworth SJ, Birchall J, Doree CJ, Hyde C (2007) Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev: CD005011Google Scholar
  16. 16.
    Conen A, Weisser M, Tsakiris DA, Siegemund M (2007) Failure of recombinant factor VIIa in a patient with severe polymicrobial sepsis and postoperative uncontrolled intraabdominal bleeding. BMC Infect Dis 7: 34PubMedCrossRefGoogle Scholar
  17. 17.
    Thomas GO, Dutton RP, Hemlock B, et al (2007) Thromboembolic complications associated with factor VIIa administration. J Trauma 62: 564–569PubMedCrossRefGoogle Scholar
  18. 18.
    Sugg RM, Gonzales NR, Matherne DE, et al (2006) Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology 67: 1053–1055PubMedCrossRefGoogle Scholar
  19. 19.
    Broderick J, Connolly S, Feldmann E, et al (2007) Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38: 2001–2023PubMedCrossRefGoogle Scholar
  20. 20.
    Mayer SA, (2007) Complications in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology 69: 319–320PubMedCrossRefGoogle Scholar
  21. 21.
    Karkouti K, Beattie WS, Wijeysundera DN, et al (2005) Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 45: 26–34PubMedCrossRefGoogle Scholar
  22. 22.
    Huber-Wagner S, Qvick M, Mussack T, et al (2007) Massive blood transfusion and outcome in 1062 polytrauma patients: a prospective study based on the Trauma Registry of the German Trauma Society. Vox Sang 92: 69–78PubMedCrossRefGoogle Scholar
  23. 23.
    Perkins JG, Schreiber MA, Wade CE, Holcomb JB (2007) Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion. J Trauma 62: 1095–1099PubMedCrossRefGoogle Scholar
  24. 24.
    Hedner U, Ezban M (2007) Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis. Annu Rev Med [Epub ahead of print]Google Scholar
  25. 25.
    Gerotziafas GT, Chakroun T, Depasse F, Arzoglou P, Samama MM, Elalamy I (2004) The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 91: 977–985PubMedGoogle Scholar
  26. 26.
    Lisman T, Adelmeijer J, Cauwenberghs S, Van Pampus EC, Heemskerk JW, De Groot PG (2005) Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 3: 742–751PubMedCrossRefGoogle Scholar
  27. 27.
    Bijsterveld NR, Moons AH, Boekholdt SM, et al (2002) Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 106: 2550–2554PubMedCrossRefGoogle Scholar
  28. 28.
    Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E (2005) A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 16: 259–266PubMedCrossRefGoogle Scholar
  29. 29.
    Wegert W, Harder S, Bassus S, Kirchmaier CM (2005) Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa. Platelets 16: 45–50PubMedCrossRefGoogle Scholar
  30. 30.
    Arkin S, Blei F, Fetten J, et al (2000) Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 11: 255–259PubMedGoogle Scholar
  31. 31.
    Negrier C, Hay CR (2000) The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost 26: 407–412PubMedCrossRefGoogle Scholar
  32. 32.
    Roberts HR, Monroe DM, 3rd, Hoffman M (2004) Safety profile of recombinant factor VIIa. Semin Hematol 41: 101–108PubMedCrossRefGoogle Scholar
  33. 33.
    Aledort LM (2004) Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2: 1700–1708PubMedCrossRefGoogle Scholar
  34. 34.
    Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ (2006) Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 46: 919–933PubMedCrossRefGoogle Scholar
  35. 35.
    O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM (2006) Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295: 293–298CrossRefGoogle Scholar
  36. 36.
    Karkouti K, Yau TM, Riazi S, et al (2006) Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anaesth 53: 802–809PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media Inc. 2008

Authors and Affiliations

  • S. Bélisle
    • 1
  • J. -F. Hardy
    • 1
  • P. Van der Linden
    • 2
  1. 1.Department of AnesthesiologyInstitut de CardiologieMontrealCanada
  2. 2.Department of AnesthesiologyCHU BrugmannBrusselsBelgium

Personalised recommendations